乙型肝炎病毒X蛋白与翻译延长因子lal（eEFlal）的相互作用及对其功能的影响
|
摘要
持续的乙型肝炎病毒(hepatitis B virus, HBV)感染可引起急慢性乙型肝炎,肝硬化,并与原发性肝细胞癌(HCC)的发生发展关系密切。全球有超过3亿的慢性感染人口,HBV致病的确切分子病理机制仍不清楚。
HBV为一种部分双链环状嗜肝DNA病毒,含4个编码病毒蛋白的开放读码框(ORF),其中一个X基因ORF编码HBV X蛋白(HBx),包含了154个氨基酸。HBx被认为是一个多功能蛋白,在病毒的感染、宿主细胞的凋亡、肝癌的发生以及参与病毒与宿主细胞相互作用的过程中都起到十分重要的作用。HBx在参与肿瘤的发生发展过程中所发挥的影响是当前HBV研究的热点。目前的研究表明,HBx的许多生物学功能需通过与其它的蛋白相互作用完成,HBx蛋白可以和许多的细胞因子相互作用,其中包括转录调控因子、细胞信号传导因子以及凋亡相关的蛋白。
鉴于已经发现了种类繁多的HBx结合蛋白,我们认为可能还存在一些目前未知的能够和HBx蛋白相互作用的细胞蛋白。为更深入研究HBx的功能,本课题第一部分,我们运用免疫沉淀(Immunoprecipitation)及随后的基质辅助激光解吸电离飞行时间质谱鉴定(MALDI-TOF- MS)的方法筛选获得了五个HBx相互作用的肝细胞蛋白,其中一个为真核延长因子1a1(Eukaryotic Elongation Factor 1 alpha 1,eEF1a1)。eEF1a1又称为真核细胞翻译延长因子1a1,是一个重要的蛋白翻译因子。eEF1a-GTP催化氨酰tRNA结合到核糖体的A位点。eEF1a1不仅是翻译必须的蛋白,而且是一个重要的多功能蛋白,参与许多重要的细胞过程和疾病,包括信号传导、翻译控制、凋亡、细胞骨架组成、病毒复制及癌基因转化等。
本课题的第二部分,通过GST pull-down实验和免疫共沉淀(Co-Immunoprecipitation,Co-IP)实验来进一步证实HBx蛋白与eEF1a1在细胞外和细胞内存在相互作用。
eEF1a1的功能包括参与蛋白翻译和促进F-肌动蛋白成束,本课题第三部分旨在研究HBx对eEF1a1相关功能的影响。结果提示HBx可以通过与eEF1a1结合,抑制细胞蛋白的总体翻译水平,减少F-肌动蛋白的成束,提示HBx通过与eEF1a1的相互作用,参与了HBV的致病性。
Persistent hepatitis B virus (HBV) infection is closely associated with the development of the acute and chronic forms of hepatitis, and with cirrhosis and hepatocellular carcinoma (HCC). But the exact molecular mechanism of how the virus inducing these diseases remains unclear.
HBV harbors a circular, partially double-stranded DNA genome consisting of four open reading frames (ORFs) that encode viral proteins. One such ORF, the X gene, encodes the 154-amino-acid HBV X protein (HBx), which has been showed to have multiple functions. HBx protein may play important role during the infection establishment, host cell apoptosis, hepatocarcinogenesis and other virus-host cell interaction processes. However, mechanism considering the association between HBx and hepatocarcinogenesis is far from been fully understood. It was proved that HBx need the help of host cell proteins to exert its function by binding to them. Current studies indicate that the HBx protein interacting with a number of host factors, including transcriptional factors and molecules involved in intracellular signaling and apoptosis.
Although many partners of HBx have been discovered, there may be many other partners remain unknown. In the first part of present study, we performed immunoprecipitation and mass spectrometry to identify Eukaryotic Elongation Factor 1 alpha 1( eEF1a1) as a novel HBx-binding protein. eEF1a1 is a major translational factor. eEF1a-GFP catalyzes the binding of aminoacyl-tRNA to the A-site of the ribosome. It is not only necessary for translation but also take part in cellular processes, including signal transduction, translational control, apoptosis, cytoskeletal organization, virus replication and oncogenic transformation.
In the second part of this study, the GST pull-down assay and the Co-immunoprecipitation(Co-IP) assay were employed to further confirming the direct interaction between HBx and eEF1a1.
In the third part of this study the influence of HBx in vitro and vivo respectively on eEF1a1 was analyzed. The results demonstrated that HBx could inhibit protein translation and reduce F-actin bundles, suggesting that HBx participated in pathogenesis of HBV through interacting with eEF1a1.
HBV为一种部分双链环状嗜肝DNA病毒,含4个编码病毒蛋白的开放读码框(ORF),其中一个X基因ORF编码HBV X蛋白(HBx),包含了154个氨基酸。HBx被认为是一个多功能蛋白,在病毒的感染、宿主细胞的凋亡、肝癌的发生以及参与病毒与宿主细胞相互作用的过程中都起到十分重要的作用。HBx在参与肿瘤的发生发展过程中所发挥的影响是当前HBV研究的热点。目前的研究表明,HBx的许多生物学功能需通过与其它的蛋白相互作用完成,HBx蛋白可以和许多的细胞因子相互作用,其中包括转录调控因子、细胞信号传导因子以及凋亡相关的蛋白。
鉴于已经发现了种类繁多的HBx结合蛋白,我们认为可能还存在一些目前未知的能够和HBx蛋白相互作用的细胞蛋白。为更深入研究HBx的功能,本课题第一部分,我们运用免疫沉淀(Immunoprecipitation)及随后的基质辅助激光解吸电离飞行时间质谱鉴定(MALDI-TOF- MS)的方法筛选获得了五个HBx相互作用的肝细胞蛋白,其中一个为真核延长因子1a1(Eukaryotic Elongation Factor 1 alpha 1,eEF1a1)。eEF1a1又称为真核细胞翻译延长因子1a1,是一个重要的蛋白翻译因子。eEF1a-GTP催化氨酰tRNA结合到核糖体的A位点。eEF1a1不仅是翻译必须的蛋白,而且是一个重要的多功能蛋白,参与许多重要的细胞过程和疾病,包括信号传导、翻译控制、凋亡、细胞骨架组成、病毒复制及癌基因转化等。
本课题的第二部分,通过GST pull-down实验和免疫共沉淀(Co-Immunoprecipitation,Co-IP)实验来进一步证实HBx蛋白与eEF1a1在细胞外和细胞内存在相互作用。
eEF1a1的功能包括参与蛋白翻译和促进F-肌动蛋白成束,本课题第三部分旨在研究HBx对eEF1a1相关功能的影响。结果提示HBx可以通过与eEF1a1结合,抑制细胞蛋白的总体翻译水平,减少F-肌动蛋白的成束,提示HBx通过与eEF1a1的相互作用,参与了HBV的致病性。
Persistent hepatitis B virus (HBV) infection is closely associated with the development of the acute and chronic forms of hepatitis, and with cirrhosis and hepatocellular carcinoma (HCC). But the exact molecular mechanism of how the virus inducing these diseases remains unclear.
HBV harbors a circular, partially double-stranded DNA genome consisting of four open reading frames (ORFs) that encode viral proteins. One such ORF, the X gene, encodes the 154-amino-acid HBV X protein (HBx), which has been showed to have multiple functions. HBx protein may play important role during the infection establishment, host cell apoptosis, hepatocarcinogenesis and other virus-host cell interaction processes. However, mechanism considering the association between HBx and hepatocarcinogenesis is far from been fully understood. It was proved that HBx need the help of host cell proteins to exert its function by binding to them. Current studies indicate that the HBx protein interacting with a number of host factors, including transcriptional factors and molecules involved in intracellular signaling and apoptosis.
Although many partners of HBx have been discovered, there may be many other partners remain unknown. In the first part of present study, we performed immunoprecipitation and mass spectrometry to identify Eukaryotic Elongation Factor 1 alpha 1( eEF1a1) as a novel HBx-binding protein. eEF1a1 is a major translational factor. eEF1a-GFP catalyzes the binding of aminoacyl-tRNA to the A-site of the ribosome. It is not only necessary for translation but also take part in cellular processes, including signal transduction, translational control, apoptosis, cytoskeletal organization, virus replication and oncogenic transformation.
In the second part of this study, the GST pull-down assay and the Co-immunoprecipitation(Co-IP) assay were employed to further confirming the direct interaction between HBx and eEF1a1.
In the third part of this study the influence of HBx in vitro and vivo respectively on eEF1a1 was analyzed. The results demonstrated that HBx could inhibit protein translation and reduce F-actin bundles, suggesting that HBx participated in pathogenesis of HBV through interacting with eEF1a1.
引文
[1] Francis V, Chisari. Viruses, Immunity, and Cancer: Lessons from Hepatitis B[J]. Am J Pathol, 2000, 156(4): 1118-1132.
[2] Guo SP, Ma ZS, Wang WL. Construction of eukaryotic expression vector of HBV x gene[J]. World J Gastroenterol, 1999, 5: 351-352.
[3] Beasley RP, Lin C-C, Hwang LY, Chen C-S. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan. Lancet. 1981,2:1129–1133.
[4] Foo NC, Ahn BY, Ma X, et al. Cellular vacuolization and apoptosis induced by hepatitis B virus large surface protein[J]. Hepatology, 2002, 36(6):1400-1407.
[5]林旭,黄清玲,郑大利,等。剪接导致截短的乙型肝炎病毒表面抗原大蛋白可诱导肝细胞空泡化[J]。中华微生物和免疫学杂志,2004, 24: 279-284.
[6] Hildt E, Saher G, Bruss V, et al. The hepatitis B virus large surface protein(LHBs) is a transcriptional activator[J].Virology, 1996, 225(1): 235-239.
[7] Hsieh YH, Su IJ, Wang HC, et al. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxide stress and DNA damage[J]. Carcinogenesis, 2004, 25(10): 2023-2032.
[8] Hildt E, Munz B, Saher G, et al. The PreS2 activator MHBst of hepatitis B virus activates c-raf-1/Erk2 signaling in transgenic mice[J]. EMBO J, 2002, 21(4): 525-535.
[9] Tabor E. Tumor suppressor genes, growth factor genes and oncogenes in hepatitis B virus-associated hepatocellular carcinoma[J]. J Med Virol, 1994, 42(4): 357-365.
[10] Tang H, Delgermaa L, Huang FJ, et al. The Transcriptional transactivation function of HBx protein is important for its augmentation role in Hepatitis B Virus replication[J]. J Virol, 2005 , 79(9): 5548-5556.
[11] Kekule AS, Laucer U, Weiss L, et al. Hepatitis B virus transactivator HBx uses a tumor promoter signaling pathway[J]. Nature, 1993, 361: 742-745.
[12] Yu FL, Liu HJ, Lee JW, et al. Hepatitis B virus X protein promotes cell migration by inducing matrix metalloproteinase-3[J]. Journal of Hepatology, 2005, 42: 520-527.
[13] Chung TW, Lee YC, Kim CH. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERKs and PI3K/ AKT pathways: involvement of invasive potential[J]. FASEB J, 2004, 18: 1123-1125
[14] Lara-Pezzi E, Gome-Gaviro MV, Galvez BG, et al. The hepatitis B virus X protein promotes tumor cells invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression[J]. J Clin Invest, 2002, 110: 1831-1838
[15] Yeh CT, Shen CH, Tai DI, et al. Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma[J]. Oncogene, 2000,19(46): 5213-5220.
[16] Hwang GY, Huang CJ, Lin CY, et al. Dominant mutations of hepatitis B virus variants in hepatoma accumulate in B-cell and T-cell epitopes of the HBx antigen.Virus Res[J]. 2003, 92(2):157-164.
[17] Rossner MT. Review: Hepatitis B virus X-gene product: A promiscuous transcriptional activator. J Med Virol.1992,36(2): 101-117.
[18] Kekulé, A., Lauer, U., Weiss, L.,et al..Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway. Nature, 1993 361:742-745.
[19] Shih, W.L., Kuo, M.L., Chuang, S.E.,et al..Hepatitis B virus X protein inhibits transforming growth factor-betainduced apoptosis through the activation of phosphatidylinositol 3-kinase pathway. J. Biol. Chem, 2000 275:25858–25864.
[20] Tu H, Bonura C, Giannini C, et al. Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res,2001;61:7803-7810.
[21] Sndrine Prost,James M.Ford,Clare Taylor,Jennifer Doi.Harison.Hepatitis B x Protein Inhibits p53-dependent DNA Repair in Primary Mouse Hepatocytes. J. Biol. Chem.1998,273(50):33327-33332.
[22] Lara-Pezzi E, Gomez-Gaviro MV, Galvez BG,et al.The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression. J Clin Invest. 2002 Dec,110(12):1831-1838.
[23] Cheong JH, YiM, LinY, Murakami S. HumanRPB5, a subunit shared by eukaryotic nuclear RNA polymerases, binds human hepatitis B virus X protein and may play a role in X transactivation. EMBO J .1995,14: 143-150.
[24] Maguire HF, Hoef?er JP, Siddiqui A. HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions. Science,1991,252: 842-844.
[25] Lee SW, LeeYM, Bae SK, Murakami S. Human hepatitis B virus X protein is a possible mediator of hypoxia-induced angiogenesis in hepatocarcinogenesis. Biochem Biophys Res Commun ,2000,268: 456-461
[26] Z.Rahmani, K.W.Huh, R.Lasher, A.Siddiqui. Hepatitis B virus X protein colocalizes to mitochondria with a human voltage-dependent anion channel, HVDAC3, and alters its transmembrane potential. J. Virol, 2000,74:2840-2846.
[27] K.H.Kim, B.L.Seong. Pro-apoptotic function of HBV X protein is mediated by interaction with c-FLIP and enhancement of death inducing signal. EMBO J, 2003,22: 2104-2116.
[28] Y Tanaka1, F Kanai, T Ichimura, K Tateishi, et al. The hepatitis B virus X protein enhances AP-1 activation through interaction with Jab1. Oncogene ,2006,25: 633-642.
[29] Masters SC. Co-immunoprecipitation from transfected cells. Methods Mol Biol,2004,261:337-50.
[30] DELPHINE SITTERLIN, TEH-HSIU LEE. Interaction of the UV-Damaged DNA-Binding Protein with Hepatitis B Virus X Protein Is Conserved among Mammalian Hepadnaviruses and Restricted to Transactivation-Proficient X-Insertion Mutants. J. Virol, 1997, 6194–6199
[31] S.M.Zhang, D.C.Sun, S.Lou, X.C.Bo, et al. HBx protein of hepatitis B virus (HBV) can form complex with mitochondrial HSP60 and HSP70. Arch Virol,2005,150(8):1579-90
[32] Buchner J. Hsp90 & Co. - a holding for folding. Trends Biochem Sci,1999,24(4):136-41.
[33] Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer,2005, 5 (10): 761–72.
[34] Christian Perotti, Ruixuan Liu, Christine T Parusel, et al. Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulation. Breast Cancer Res,2008,10(6): R94.
[35] Abbott CM, Proud CG. Translation factors: in sickness and in health, Trends Biochem Sci, 2004, 29(1): 25-31.
[36] Lund A, Knudsen SM, Vissing H, et al, Assignment of human elongation factor 1alpha genes: EEF1A maps to chromosome 6q14 and EEF1A2 to 20q13.3. Genomics, 1996, 36(2): 359–361.
[37] Lukash TO, Turkivksa HV, Negrutskii BS, et al. Chapeorne-like acitvtiy of mammalian elongation factor eEF1A: renaturation of amnioacyl-tRNAs synthetases. Int J Biochem Cell Biol, 2004, 36(7): 1341-1347.
[38]周冰,曹诚,刘传。翻译延伸因子1A的研究进展[J]。生物技术通讯,2007,18(2):281-284。
[39] Yang F, Demma M, Warren V, et al, Identification of an actin-binding protein from Dictyostelium as elongation factor la. Nature, 1990, 347(6292): 494-496.
[40] Duttaroy A, Bourbeau D, Wang XL, et a1. Apoptosis rate can be accelerated or decelerated by overexpression or reduction of the level of elongation factor-1 alpha. Exp Cell Res, 1998, 238(1):168-176.
[41] Grant AG, Flomen RM, Tizard ML, Differential screening of a human pancreatic adenocarcinoma lambda gt11 expression library has identified increased transcription of elongation factor EF-1 alpha in tumour cells, Int J Cancer, 1992, 50 (5) 740-745.
[42] Tomlinson VA, Newbery HJ, Wray NR, et al, Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours. BMC Cancer 2005, 5: 113.
[43] Anand N, Murthy S, Amann G, et al, Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer, Nat Genet, 2002, 31 (3): 301-305.
[44] Lee JM, The role of protein elongation factor eEF1A2 in ovarian cancer, Reprod Biol Endocrinol, 2003,1: 69.
[45] J.萨母布鲁克,D.W.拉塞尔.分子克隆实验指南,第三版.北京:科学出版社,2002:1217.
[46] Brinkmann U, Mattes RE, Buckel P.High-level expression of recombinant genes in Escherichia coli is dependent on the availability of the dnaY gene product. Gene.1989 Dec 21;85(1):109-14.
[47] Del Tito BJ Jr, Ward JM, Hodgson J, Gershater CJ.Effects of a minor isoleucyl tRNA on heterologous protein translation in Escherichia coli. J Bacteriol. 1995 Dec;177(24):7086-91.
[48] Yang F, M Demma, V Warren, S Dharmawardhane, J Condeelis. Identification of an actin-binding protein from Dictyostelium as elongation factor 1a. Nature,1990, 347:494–496.
[49] Kurasawa Y, Y Watanabe, O Numata. Characterization of F-actin bundling activity of Tetrahymena elongation factor 1 alpha investigated with rabbit skeletal muscle actin. Zoolog. Sci,1996,13:371–375.
[50] Bunai F, Ando K, Ueno H, et al. Tetrahymena eukaryotic translation elongation factor 1A(eEF1A) bundles filamentous actin through dimer formation. J. Biochem, 2006,140:393-399 .
[51] Davis, G.D., Elisee, C., Newham, D.M. and R.G. Harrison. New fusion protein systems designed to give soluble expression in Escherichia coli. Biotechnol. Bioeng. 1999, 65(4):382-8.
[52] R.G. Harrison. Expression of soluble heterologous proteins via fusion with NusA protein. in Novations. 2000,11:4-7.
[53] Zheng DL, Zhang L, Cheng N, et al. Epigenetic modification induced by hepatitis B virus X protein via interaction with de novo DNA methyltransferase DNMT3A. J Hepatol, 2009,50:377-387.
[54] Pollicino T, Belloni L, Raffa G, et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology, 2006,130:823-837.
[55] Belloni L, Pollicino T, De Nicola F, et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci,2009,106:19975-19979.
[56] Narayan R, Gangadharan B, Hantz O, Antrobus R. Proteomic analysis of HepaRG cells: a novel cell line that supports hepatitis B virus infection. J Proteome Res,2009,8(1):118-22.
[57] Tong A, Wu L, Lin Q, Lau QC, Zhao X. Proteomic analysis of cellular protein alterations using a hepatitis B virus-producing cellular model. Proteomics,2008,8(10):2012-23.
[58] Tong A, Gou L, Lau QC, Chen B, Zhao X. Proteomic profiling identifies aberrant epigenetic modifications induced by hepatitis B virus X protein. J Proteome Res, 2009,8(2):1037-46.
[59] Cui F, Wang Y, Wang J, Wei K, Hu J. The up-regulation of proteasome subunits and lysosomal proteases in hepatocellular carcinomas of the HBx gene knockin transgenic mice. Proteomics,2006,6(2):498-504.
[60] Kim SY, Lee PY, Shin HJ, Kim do H. Proteomic analysis of liver tissue from HBx-transgenic mice at early stages of hepatocarcinogenesis. Proteomics,2009,9(22):5056-66.
[61] Gross SR, Kinzy TG. Translation elongation factor 1A is essential for regulation of the actin cytoskeleton and cell morphology. Nature Structural& Molecular Biology, 2005, 12(9): 772-778.
[62] Samstag Y, Eibert SM, Klemke M, Wabnitz GH. Actin cytoskeletal dynamics in T lymphocyte activation and migration. J Leukoc Biol,2003 ,73(1):30-48.
[63] Dominguez R, Holmes KC. Actin Structure And Function. Annu Rev Biophys,2010 Jul 21.
[64] Zheng B, Han M, Bernier M, Wen JK. Nuclear actin and actin-binding proteins in the regulation of transcription and gene expression. FEBS J. 2009,276(10):2669-85.
[65] Glotzer M. The mechanism and control of cytokinesis. Curr Opin Cell Biol. 1997,9(6):815-23.
[66] Robinson DN, Spudich JA. Towards a molecular understanding of cytokinesis. Trends Cell Biol. 2000,10(6):228-37.
[1] Abbott CM, Proud CG, Translation factors: in sickness and in health, Trends Biochem Sci, 2004, 29(1): 25-31.
[2] Lund A, Knudsen SM, Vissing H, et al, Assignment of human elongation factor 1alpha genes: EEF1A maps to chromosome 6q14 and EEF1A2 to 20q13.3. Genomics, 1996, 36(2): 359–361.
[3] Lee S, Francoeur AM, Liu S, Tissue-specific expression in mammalian brain, heart, and muscle of S1, a member of the elongation factor-1 alpha gene family. J Biol Chem, 1992, 267(33): 24064–24068.
[4] Knudsen SM, Frydenberg J, Clark BF, et al, Tissue-dependent variation in the expression of elongation factor-1 alpha isoforms: isolation and characterisation of a cDNA encoding a novel variant of human elongation-factor 1 alpha, Eur J Biochem, 1993, 215(3): 549-554.
[5]Lukash TO, Turkivksa HV, Negrutskii BS, et al. Chapeorne-like acitvtiy of mammalian elongation factor eEF1A: renaturation of amnioacyl-tRNAs synthetases. Int J Biochem Cell Biol, 2004, 36(7): 1341-1347.
[6] Hotokezaka Y, Tobben U, Hotokezaka H, et a1. Interaction of the eukaryotic elongation factor 1A with newly synthesized polypeptides. J Biol Chem, 2002, 277(21): 18545-18551.
[7] Condeelis J, Elongation factor 1 alpha, translation and the cytoskeleton. Trends Biochem Sci, 1995, 20(5): 169-170.
[8] Bekta? M, Nurten R, Gürel Z, et al, Interactions of eukaryotic elongation factor 2 with actin: a possible link between protein synthetic machinery and cytoskeleton, FEBS Lett, 1994, 356(1): 89-93.
[9] Gross SR, Kinzy TG, Translation elongation factor 1A is essential for regulation of the actin cytoskeleton and cell morphology. Nat. Struct. Mol. Biol, 2005, 12(9): 772-778.
[10]周冰,曹诚,刘传。翻译延伸因子1A的研究进展[J]。生物技术通讯,2007,18(2):281-284。
[11] Yang F, Demma M, Warren V, et al, Identification of an actin-binding protein from Dictyostelium as elongation factor la. Nature, 1990, 347(6292): 494-496.
[12] Muray JW, Edmonds BT, Iifu G, et al. Bundling of actin iflaments by elongationfactor 1 alpha inhibits polymerization at filament ends. J Cell Biol, 1996, 135(5): 1309.
[13] Moore R C, Durso N A, Cyr R J, Elongation factor-lalpha stabilizes microtubules in a calcium/calmodulin-dependent manner. Cell Motil Cytoskeleton, 1998, 41(2): 168.
[14] Moore RC, Cyr RJ. Association between elongation factor-lalpha and microtubules vivo is domain dependent and conditional. Cell Motil Cytoskeleton, 2000, 45(4): 279.
[15] Liu G, Tang J, Edmonds BT, et al, F-actin sequesters elongation factor lalpha from interaction with aminoacyl-tRNA in a pH-dependent reaction. The Jounral of Cell Bioloyg, 1996, 135(4): 953-963.
[16] Kandl KA, Munshl R, Ortiz PA, et al, Identification of a role for actin in translational fidelity in yeast. Molecular Genetics and Genomies, 2002, 268(1): 10-18.
[17] Gross SR, Kinzy TG. Translation elongation factor 1A is essential for regulation of the actin cytoskeleton and cell morphology. Nature Structural& Molecular Biology, 2005, 12(9): 772-778.
[18] Kato MV, Sato H, Nagayoshi M, et a1. Upregulation of the elongation factor-1 alpha gene by p53 in association with death of anerythroleukemic cell line. Blood, 1997, 90(4): 1373-1378.
[19] Duttaroy A, Bourbeau D, Wang XL, et a1. Apoptosis rate can be accelerated or decelerated by overexpression or reduction of the level of elongation factor-1 alpha. Exp Cell Res, 1998, 238(1):168-176.
[20] Chen E, Porestou G, Bourbeau D, et a1. Rapid upreuglation of peptide elongation factor EF-1 alpha protein levels is an immediate early event during oxidative stress—induced apoptosis. Exp Cell Res, 2000, 259(1): 140.
[21] Talapatra S, Wagner JD, Thompson CB, Elongation factor-1 alpha is a selective regulator of growth factor withdrawal and ER stress-induced apoptosis, Cell Death Differ, 2002, 9(8): 856-861.
[22] Johnsson A, Zeelenberg I, Min Y, et al, Identification of genes differentially expressed in association with acquired cisplatin resistance, Br J Cancer, 2000,83(8): 1047-1054.
[23] Chambers DM, Petesr J, Abobtt CM. The lethal mutatiton of the mouse wasted (wst) is a deletion that abolishes expression of a tissue-specific isoform of translation elongation facotor lalpha encoded by the eEF1A2 gene. Proc Natl AcadSci USA, 1998, 95: 4463-4468.
[24] Potter M, Bernstein A, Lee JM, The wst gene regulates multiple forms of thymocyte apoptosis, Cell Immunol, 1998, 188(2): 111-117.
[25] Ruets LB, Mar cote R, Wang E. Peptide elongaiton factor eEF1A2-/S1 experssion in cultured differentiated mytubes and its protective effect against caspase3-mediated apoptosis[J]. J Biol Chem, 2002, 277(7): 5418-5425.
[26] Lichter P, Multicolor FISHing: what’s the catch? Trends Genet, 1997,13(12): 475-479.
[27] Cavallius J, Rattan SI, Clark BF, Changes in activity and amount of active elongation factor 1 alpha in aging and immortal human fibroblast cultures, Exp. Gerontol, 1986, 21(3): 149-157.
[28] Duttaroy A, Bourbeau D, Wang XL, et al. Apoptosis rate can be accelerated or decelerated by overexpression or reduction of the level of elongation factor-1 alpha, Exp. Cell Res, 1998, 238(1): 168-176.
[29] Scaggiante B, Dapas B, Grassi G, et al, Interaction of G-rich GT oligonucleotides with nuclear-associated eEF1A is correlated with their antiproliferative effect in haematopoietic human cancer cell lines, FEBS J, 2006, 273(7): 1350-1361.
[30] Gangwani L, Mikrut M, Galcheva-Gargova Z, et al, Interaction of ZPR1 with translation elongation factor-1alpha in proliferating cells, J. Cell Biol, 1998,143: 1471-1484.
[31] de Wit NJ, Burtscher HJ, Weidle UH, et al, Differentially expressed genes identified in human melanoma cell lines with different metastatic behaviour using high density oligonucleotide arrays, Melanoma Res, 2002, 12(1)57-69.
[32] Grant AG, Flomen RM, Tizard ML, Differential screening of a human pancreatic adenocarcinoma lambda gt11 expression library has identified increased transcription of elongation factor EF-1 alpha in tumour cells, Int J Cancer 1992, 50 (5) 740-745.
[33] Edmonds BT, Wyckoff J, Yeung YG, et al, Elongation factor-1 alpha is an overexpressed actin binding protein in metastatic rat mammary adenocarcinoma, J Cell Sci, 1996, 109(Pt 11) 2705-2714.
[34] Tanner MM, Grenman S, Koul A, et al, Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer, Clin Cancer Res, 2000, 6 (5): 1833-1839.
[35] Hodgson JG, Chin K, Collins C, et al, Genome amplification of chromosome 20 in breast cancer, Breast Cancer Res. Treat 2003, 78 (3): 337-345.
[36] Schlegel J, Stumm G, Scherthan H, et al, Comparative genomic in situhybridization of colon carcinomas with replication error, Cancer Res,1995, 55(24): 6002-6005.
[37] Diebold J, Mosinger K, Peiro G, et a1. 20q13 and cyclin D1 in ovarian carcinomas. Analysis by fluorescence in situ hybridization. J Pathol, 2000, 190 (5): 564-571.
[38] Anand N, Murthy S, Amann G, et al, Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer, Nat Genet, 2002, 31 (3): 301-305.
[39] Grassi G, Scaggiante B, Farra R, et al, The expression levels of the translational factors eEF1A 1/2 correlate with cell growth but not apoptosis in hepatocellular carcinoma cell lines with different differentiation grade. Biochimie, 2007, 89 (12): 1544-1552.
[40] Wu C, Luo Z, Chen X, et al, Two-dimensional differential in-gel electrophoresis for identification of gastric cancer-specific protein markers, Oncol Rep, 2009, 21(6): 1429-1437.
[41] Lee JM, The role of protein elongation factor eEF1A2 in ovarian cancer, Reprod Biol Endocrinol, 2003,1: 69.
[42] Dapas B, Tell G Scaloni A, et a1. Identification of diferent isoforms of eEF1A in the nuclear fraction of human T-lymphoblasitc cancer cell line specifically binding to aptameric cytotoxic GT olgiomers. Eur J Biochem, 2003, 270(15): 3251-3262.
[43] Tomlinson VA, Newbery HJ, Bergmann JH, et al, Expression of eEF1A2 is associated with clear cell histology in ovarian carcinomas: overexpression of the gene is not dependent on modifications at the EEF1A2 locus. British Journal of Cancer, 2007, 96(10): 1613-1620.
[44] Tomlinson VA, Newbery HJ, Wray NR, et al, Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours. BMC Cancer 2005, 5: 113.
[2] Guo SP, Ma ZS, Wang WL. Construction of eukaryotic expression vector of HBV x gene[J]. World J Gastroenterol, 1999, 5: 351-352.
[3] Beasley RP, Lin C-C, Hwang LY, Chen C-S. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan. Lancet. 1981,2:1129–1133.
[4] Foo NC, Ahn BY, Ma X, et al. Cellular vacuolization and apoptosis induced by hepatitis B virus large surface protein[J]. Hepatology, 2002, 36(6):1400-1407.
[5]林旭,黄清玲,郑大利,等。剪接导致截短的乙型肝炎病毒表面抗原大蛋白可诱导肝细胞空泡化[J]。中华微生物和免疫学杂志,2004, 24: 279-284.
[6] Hildt E, Saher G, Bruss V, et al. The hepatitis B virus large surface protein(LHBs) is a transcriptional activator[J].Virology, 1996, 225(1): 235-239.
[7] Hsieh YH, Su IJ, Wang HC, et al. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxide stress and DNA damage[J]. Carcinogenesis, 2004, 25(10): 2023-2032.
[8] Hildt E, Munz B, Saher G, et al. The PreS2 activator MHBst of hepatitis B virus activates c-raf-1/Erk2 signaling in transgenic mice[J]. EMBO J, 2002, 21(4): 525-535.
[9] Tabor E. Tumor suppressor genes, growth factor genes and oncogenes in hepatitis B virus-associated hepatocellular carcinoma[J]. J Med Virol, 1994, 42(4): 357-365.
[10] Tang H, Delgermaa L, Huang FJ, et al. The Transcriptional transactivation function of HBx protein is important for its augmentation role in Hepatitis B Virus replication[J]. J Virol, 2005 , 79(9): 5548-5556.
[11] Kekule AS, Laucer U, Weiss L, et al. Hepatitis B virus transactivator HBx uses a tumor promoter signaling pathway[J]. Nature, 1993, 361: 742-745.
[12] Yu FL, Liu HJ, Lee JW, et al. Hepatitis B virus X protein promotes cell migration by inducing matrix metalloproteinase-3[J]. Journal of Hepatology, 2005, 42: 520-527.
[13] Chung TW, Lee YC, Kim CH. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERKs and PI3K/ AKT pathways: involvement of invasive potential[J]. FASEB J, 2004, 18: 1123-1125
[14] Lara-Pezzi E, Gome-Gaviro MV, Galvez BG, et al. The hepatitis B virus X protein promotes tumor cells invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression[J]. J Clin Invest, 2002, 110: 1831-1838
[15] Yeh CT, Shen CH, Tai DI, et al. Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma[J]. Oncogene, 2000,19(46): 5213-5220.
[16] Hwang GY, Huang CJ, Lin CY, et al. Dominant mutations of hepatitis B virus variants in hepatoma accumulate in B-cell and T-cell epitopes of the HBx antigen.Virus Res[J]. 2003, 92(2):157-164.
[17] Rossner MT. Review: Hepatitis B virus X-gene product: A promiscuous transcriptional activator. J Med Virol.1992,36(2): 101-117.
[18] Kekulé, A., Lauer, U., Weiss, L.,et al..Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway. Nature, 1993 361:742-745.
[19] Shih, W.L., Kuo, M.L., Chuang, S.E.,et al..Hepatitis B virus X protein inhibits transforming growth factor-betainduced apoptosis through the activation of phosphatidylinositol 3-kinase pathway. J. Biol. Chem, 2000 275:25858–25864.
[20] Tu H, Bonura C, Giannini C, et al. Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res,2001;61:7803-7810.
[21] Sndrine Prost,James M.Ford,Clare Taylor,Jennifer Doi.Harison.Hepatitis B x Protein Inhibits p53-dependent DNA Repair in Primary Mouse Hepatocytes. J. Biol. Chem.1998,273(50):33327-33332.
[22] Lara-Pezzi E, Gomez-Gaviro MV, Galvez BG,et al.The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression. J Clin Invest. 2002 Dec,110(12):1831-1838.
[23] Cheong JH, YiM, LinY, Murakami S. HumanRPB5, a subunit shared by eukaryotic nuclear RNA polymerases, binds human hepatitis B virus X protein and may play a role in X transactivation. EMBO J .1995,14: 143-150.
[24] Maguire HF, Hoef?er JP, Siddiqui A. HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions. Science,1991,252: 842-844.
[25] Lee SW, LeeYM, Bae SK, Murakami S. Human hepatitis B virus X protein is a possible mediator of hypoxia-induced angiogenesis in hepatocarcinogenesis. Biochem Biophys Res Commun ,2000,268: 456-461
[26] Z.Rahmani, K.W.Huh, R.Lasher, A.Siddiqui. Hepatitis B virus X protein colocalizes to mitochondria with a human voltage-dependent anion channel, HVDAC3, and alters its transmembrane potential. J. Virol, 2000,74:2840-2846.
[27] K.H.Kim, B.L.Seong. Pro-apoptotic function of HBV X protein is mediated by interaction with c-FLIP and enhancement of death inducing signal. EMBO J, 2003,22: 2104-2116.
[28] Y Tanaka1, F Kanai, T Ichimura, K Tateishi, et al. The hepatitis B virus X protein enhances AP-1 activation through interaction with Jab1. Oncogene ,2006,25: 633-642.
[29] Masters SC. Co-immunoprecipitation from transfected cells. Methods Mol Biol,2004,261:337-50.
[30] DELPHINE SITTERLIN, TEH-HSIU LEE. Interaction of the UV-Damaged DNA-Binding Protein with Hepatitis B Virus X Protein Is Conserved among Mammalian Hepadnaviruses and Restricted to Transactivation-Proficient X-Insertion Mutants. J. Virol, 1997, 6194–6199
[31] S.M.Zhang, D.C.Sun, S.Lou, X.C.Bo, et al. HBx protein of hepatitis B virus (HBV) can form complex with mitochondrial HSP60 and HSP70. Arch Virol,2005,150(8):1579-90
[32] Buchner J. Hsp90 & Co. - a holding for folding. Trends Biochem Sci,1999,24(4):136-41.
[33] Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer,2005, 5 (10): 761–72.
[34] Christian Perotti, Ruixuan Liu, Christine T Parusel, et al. Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulation. Breast Cancer Res,2008,10(6): R94.
[35] Abbott CM, Proud CG. Translation factors: in sickness and in health, Trends Biochem Sci, 2004, 29(1): 25-31.
[36] Lund A, Knudsen SM, Vissing H, et al, Assignment of human elongation factor 1alpha genes: EEF1A maps to chromosome 6q14 and EEF1A2 to 20q13.3. Genomics, 1996, 36(2): 359–361.
[37] Lukash TO, Turkivksa HV, Negrutskii BS, et al. Chapeorne-like acitvtiy of mammalian elongation factor eEF1A: renaturation of amnioacyl-tRNAs synthetases. Int J Biochem Cell Biol, 2004, 36(7): 1341-1347.
[38]周冰,曹诚,刘传。翻译延伸因子1A的研究进展[J]。生物技术通讯,2007,18(2):281-284。
[39] Yang F, Demma M, Warren V, et al, Identification of an actin-binding protein from Dictyostelium as elongation factor la. Nature, 1990, 347(6292): 494-496.
[40] Duttaroy A, Bourbeau D, Wang XL, et a1. Apoptosis rate can be accelerated or decelerated by overexpression or reduction of the level of elongation factor-1 alpha. Exp Cell Res, 1998, 238(1):168-176.
[41] Grant AG, Flomen RM, Tizard ML, Differential screening of a human pancreatic adenocarcinoma lambda gt11 expression library has identified increased transcription of elongation factor EF-1 alpha in tumour cells, Int J Cancer, 1992, 50 (5) 740-745.
[42] Tomlinson VA, Newbery HJ, Wray NR, et al, Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours. BMC Cancer 2005, 5: 113.
[43] Anand N, Murthy S, Amann G, et al, Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer, Nat Genet, 2002, 31 (3): 301-305.
[44] Lee JM, The role of protein elongation factor eEF1A2 in ovarian cancer, Reprod Biol Endocrinol, 2003,1: 69.
[45] J.萨母布鲁克,D.W.拉塞尔.分子克隆实验指南,第三版.北京:科学出版社,2002:1217.
[46] Brinkmann U, Mattes RE, Buckel P.High-level expression of recombinant genes in Escherichia coli is dependent on the availability of the dnaY gene product. Gene.1989 Dec 21;85(1):109-14.
[47] Del Tito BJ Jr, Ward JM, Hodgson J, Gershater CJ.Effects of a minor isoleucyl tRNA on heterologous protein translation in Escherichia coli. J Bacteriol. 1995 Dec;177(24):7086-91.
[48] Yang F, M Demma, V Warren, S Dharmawardhane, J Condeelis. Identification of an actin-binding protein from Dictyostelium as elongation factor 1a. Nature,1990, 347:494–496.
[49] Kurasawa Y, Y Watanabe, O Numata. Characterization of F-actin bundling activity of Tetrahymena elongation factor 1 alpha investigated with rabbit skeletal muscle actin. Zoolog. Sci,1996,13:371–375.
[50] Bunai F, Ando K, Ueno H, et al. Tetrahymena eukaryotic translation elongation factor 1A(eEF1A) bundles filamentous actin through dimer formation. J. Biochem, 2006,140:393-399 .
[51] Davis, G.D., Elisee, C., Newham, D.M. and R.G. Harrison. New fusion protein systems designed to give soluble expression in Escherichia coli. Biotechnol. Bioeng. 1999, 65(4):382-8.
[52] R.G. Harrison. Expression of soluble heterologous proteins via fusion with NusA protein. in Novations. 2000,11:4-7.
[53] Zheng DL, Zhang L, Cheng N, et al. Epigenetic modification induced by hepatitis B virus X protein via interaction with de novo DNA methyltransferase DNMT3A. J Hepatol, 2009,50:377-387.
[54] Pollicino T, Belloni L, Raffa G, et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology, 2006,130:823-837.
[55] Belloni L, Pollicino T, De Nicola F, et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci,2009,106:19975-19979.
[56] Narayan R, Gangadharan B, Hantz O, Antrobus R. Proteomic analysis of HepaRG cells: a novel cell line that supports hepatitis B virus infection. J Proteome Res,2009,8(1):118-22.
[57] Tong A, Wu L, Lin Q, Lau QC, Zhao X. Proteomic analysis of cellular protein alterations using a hepatitis B virus-producing cellular model. Proteomics,2008,8(10):2012-23.
[58] Tong A, Gou L, Lau QC, Chen B, Zhao X. Proteomic profiling identifies aberrant epigenetic modifications induced by hepatitis B virus X protein. J Proteome Res, 2009,8(2):1037-46.
[59] Cui F, Wang Y, Wang J, Wei K, Hu J. The up-regulation of proteasome subunits and lysosomal proteases in hepatocellular carcinomas of the HBx gene knockin transgenic mice. Proteomics,2006,6(2):498-504.
[60] Kim SY, Lee PY, Shin HJ, Kim do H. Proteomic analysis of liver tissue from HBx-transgenic mice at early stages of hepatocarcinogenesis. Proteomics,2009,9(22):5056-66.
[61] Gross SR, Kinzy TG. Translation elongation factor 1A is essential for regulation of the actin cytoskeleton and cell morphology. Nature Structural& Molecular Biology, 2005, 12(9): 772-778.
[62] Samstag Y, Eibert SM, Klemke M, Wabnitz GH. Actin cytoskeletal dynamics in T lymphocyte activation and migration. J Leukoc Biol,2003 ,73(1):30-48.
[63] Dominguez R, Holmes KC. Actin Structure And Function. Annu Rev Biophys,2010 Jul 21.
[64] Zheng B, Han M, Bernier M, Wen JK. Nuclear actin and actin-binding proteins in the regulation of transcription and gene expression. FEBS J. 2009,276(10):2669-85.
[65] Glotzer M. The mechanism and control of cytokinesis. Curr Opin Cell Biol. 1997,9(6):815-23.
[66] Robinson DN, Spudich JA. Towards a molecular understanding of cytokinesis. Trends Cell Biol. 2000,10(6):228-37.
[1] Abbott CM, Proud CG, Translation factors: in sickness and in health, Trends Biochem Sci, 2004, 29(1): 25-31.
[2] Lund A, Knudsen SM, Vissing H, et al, Assignment of human elongation factor 1alpha genes: EEF1A maps to chromosome 6q14 and EEF1A2 to 20q13.3. Genomics, 1996, 36(2): 359–361.
[3] Lee S, Francoeur AM, Liu S, Tissue-specific expression in mammalian brain, heart, and muscle of S1, a member of the elongation factor-1 alpha gene family. J Biol Chem, 1992, 267(33): 24064–24068.
[4] Knudsen SM, Frydenberg J, Clark BF, et al, Tissue-dependent variation in the expression of elongation factor-1 alpha isoforms: isolation and characterisation of a cDNA encoding a novel variant of human elongation-factor 1 alpha, Eur J Biochem, 1993, 215(3): 549-554.
[5]Lukash TO, Turkivksa HV, Negrutskii BS, et al. Chapeorne-like acitvtiy of mammalian elongation factor eEF1A: renaturation of amnioacyl-tRNAs synthetases. Int J Biochem Cell Biol, 2004, 36(7): 1341-1347.
[6] Hotokezaka Y, Tobben U, Hotokezaka H, et a1. Interaction of the eukaryotic elongation factor 1A with newly synthesized polypeptides. J Biol Chem, 2002, 277(21): 18545-18551.
[7] Condeelis J, Elongation factor 1 alpha, translation and the cytoskeleton. Trends Biochem Sci, 1995, 20(5): 169-170.
[8] Bekta? M, Nurten R, Gürel Z, et al, Interactions of eukaryotic elongation factor 2 with actin: a possible link between protein synthetic machinery and cytoskeleton, FEBS Lett, 1994, 356(1): 89-93.
[9] Gross SR, Kinzy TG, Translation elongation factor 1A is essential for regulation of the actin cytoskeleton and cell morphology. Nat. Struct. Mol. Biol, 2005, 12(9): 772-778.
[10]周冰,曹诚,刘传。翻译延伸因子1A的研究进展[J]。生物技术通讯,2007,18(2):281-284。
[11] Yang F, Demma M, Warren V, et al, Identification of an actin-binding protein from Dictyostelium as elongation factor la. Nature, 1990, 347(6292): 494-496.
[12] Muray JW, Edmonds BT, Iifu G, et al. Bundling of actin iflaments by elongationfactor 1 alpha inhibits polymerization at filament ends. J Cell Biol, 1996, 135(5): 1309.
[13] Moore R C, Durso N A, Cyr R J, Elongation factor-lalpha stabilizes microtubules in a calcium/calmodulin-dependent manner. Cell Motil Cytoskeleton, 1998, 41(2): 168.
[14] Moore RC, Cyr RJ. Association between elongation factor-lalpha and microtubules vivo is domain dependent and conditional. Cell Motil Cytoskeleton, 2000, 45(4): 279.
[15] Liu G, Tang J, Edmonds BT, et al, F-actin sequesters elongation factor lalpha from interaction with aminoacyl-tRNA in a pH-dependent reaction. The Jounral of Cell Bioloyg, 1996, 135(4): 953-963.
[16] Kandl KA, Munshl R, Ortiz PA, et al, Identification of a role for actin in translational fidelity in yeast. Molecular Genetics and Genomies, 2002, 268(1): 10-18.
[17] Gross SR, Kinzy TG. Translation elongation factor 1A is essential for regulation of the actin cytoskeleton and cell morphology. Nature Structural& Molecular Biology, 2005, 12(9): 772-778.
[18] Kato MV, Sato H, Nagayoshi M, et a1. Upregulation of the elongation factor-1 alpha gene by p53 in association with death of anerythroleukemic cell line. Blood, 1997, 90(4): 1373-1378.
[19] Duttaroy A, Bourbeau D, Wang XL, et a1. Apoptosis rate can be accelerated or decelerated by overexpression or reduction of the level of elongation factor-1 alpha. Exp Cell Res, 1998, 238(1):168-176.
[20] Chen E, Porestou G, Bourbeau D, et a1. Rapid upreuglation of peptide elongation factor EF-1 alpha protein levels is an immediate early event during oxidative stress—induced apoptosis. Exp Cell Res, 2000, 259(1): 140.
[21] Talapatra S, Wagner JD, Thompson CB, Elongation factor-1 alpha is a selective regulator of growth factor withdrawal and ER stress-induced apoptosis, Cell Death Differ, 2002, 9(8): 856-861.
[22] Johnsson A, Zeelenberg I, Min Y, et al, Identification of genes differentially expressed in association with acquired cisplatin resistance, Br J Cancer, 2000,83(8): 1047-1054.
[23] Chambers DM, Petesr J, Abobtt CM. The lethal mutatiton of the mouse wasted (wst) is a deletion that abolishes expression of a tissue-specific isoform of translation elongation facotor lalpha encoded by the eEF1A2 gene. Proc Natl AcadSci USA, 1998, 95: 4463-4468.
[24] Potter M, Bernstein A, Lee JM, The wst gene regulates multiple forms of thymocyte apoptosis, Cell Immunol, 1998, 188(2): 111-117.
[25] Ruets LB, Mar cote R, Wang E. Peptide elongaiton factor eEF1A2-/S1 experssion in cultured differentiated mytubes and its protective effect against caspase3-mediated apoptosis[J]. J Biol Chem, 2002, 277(7): 5418-5425.
[26] Lichter P, Multicolor FISHing: what’s the catch? Trends Genet, 1997,13(12): 475-479.
[27] Cavallius J, Rattan SI, Clark BF, Changes in activity and amount of active elongation factor 1 alpha in aging and immortal human fibroblast cultures, Exp. Gerontol, 1986, 21(3): 149-157.
[28] Duttaroy A, Bourbeau D, Wang XL, et al. Apoptosis rate can be accelerated or decelerated by overexpression or reduction of the level of elongation factor-1 alpha, Exp. Cell Res, 1998, 238(1): 168-176.
[29] Scaggiante B, Dapas B, Grassi G, et al, Interaction of G-rich GT oligonucleotides with nuclear-associated eEF1A is correlated with their antiproliferative effect in haematopoietic human cancer cell lines, FEBS J, 2006, 273(7): 1350-1361.
[30] Gangwani L, Mikrut M, Galcheva-Gargova Z, et al, Interaction of ZPR1 with translation elongation factor-1alpha in proliferating cells, J. Cell Biol, 1998,143: 1471-1484.
[31] de Wit NJ, Burtscher HJ, Weidle UH, et al, Differentially expressed genes identified in human melanoma cell lines with different metastatic behaviour using high density oligonucleotide arrays, Melanoma Res, 2002, 12(1)57-69.
[32] Grant AG, Flomen RM, Tizard ML, Differential screening of a human pancreatic adenocarcinoma lambda gt11 expression library has identified increased transcription of elongation factor EF-1 alpha in tumour cells, Int J Cancer 1992, 50 (5) 740-745.
[33] Edmonds BT, Wyckoff J, Yeung YG, et al, Elongation factor-1 alpha is an overexpressed actin binding protein in metastatic rat mammary adenocarcinoma, J Cell Sci, 1996, 109(Pt 11) 2705-2714.
[34] Tanner MM, Grenman S, Koul A, et al, Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer, Clin Cancer Res, 2000, 6 (5): 1833-1839.
[35] Hodgson JG, Chin K, Collins C, et al, Genome amplification of chromosome 20 in breast cancer, Breast Cancer Res. Treat 2003, 78 (3): 337-345.
[36] Schlegel J, Stumm G, Scherthan H, et al, Comparative genomic in situhybridization of colon carcinomas with replication error, Cancer Res,1995, 55(24): 6002-6005.
[37] Diebold J, Mosinger K, Peiro G, et a1. 20q13 and cyclin D1 in ovarian carcinomas. Analysis by fluorescence in situ hybridization. J Pathol, 2000, 190 (5): 564-571.
[38] Anand N, Murthy S, Amann G, et al, Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer, Nat Genet, 2002, 31 (3): 301-305.
[39] Grassi G, Scaggiante B, Farra R, et al, The expression levels of the translational factors eEF1A 1/2 correlate with cell growth but not apoptosis in hepatocellular carcinoma cell lines with different differentiation grade. Biochimie, 2007, 89 (12): 1544-1552.
[40] Wu C, Luo Z, Chen X, et al, Two-dimensional differential in-gel electrophoresis for identification of gastric cancer-specific protein markers, Oncol Rep, 2009, 21(6): 1429-1437.
[41] Lee JM, The role of protein elongation factor eEF1A2 in ovarian cancer, Reprod Biol Endocrinol, 2003,1: 69.
[42] Dapas B, Tell G Scaloni A, et a1. Identification of diferent isoforms of eEF1A in the nuclear fraction of human T-lymphoblasitc cancer cell line specifically binding to aptameric cytotoxic GT olgiomers. Eur J Biochem, 2003, 270(15): 3251-3262.
[43] Tomlinson VA, Newbery HJ, Bergmann JH, et al, Expression of eEF1A2 is associated with clear cell histology in ovarian carcinomas: overexpression of the gene is not dependent on modifications at the EEF1A2 locus. British Journal of Cancer, 2007, 96(10): 1613-1620.
[44] Tomlinson VA, Newbery HJ, Wray NR, et al, Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours. BMC Cancer 2005, 5: 113.